Androexpertise Clinic, Istanbul, Turkey.
Department of Urology, Memorial Bahcelievler Hospital, Istanbul, Turkey.
Aging Male. 2023 Dec;26(1):2253876. doi: 10.1080/13685538.2023.2253876.
This study aims to evaluate the long-term effectiveness of Li-ESWT in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) patients and to compare the effect of treatment protocol differences on success.
Between December 2019 and January 2021, the data of male patients over the age of 18 who applied to the urology outpatient clinic with CP/CPPS symptoms were retrospectively analyzed. International Prostate Symptom Index (IPSS) and International Index of Erectile Function-Erectile Function (IIEF-EF) questionnaires were filled in for the evaluation of erectile function. All patients received treatment with the Medispect Bold Li-ESWT. The treatment responses of the patients who received a total of 6 sessions from one session per week and 12 sessions from two sessions per week were compared.
A total of 129 patients were included in the study. Significant improvements were observed in the NIH-CPSI, IPSS, and IIEF-EF scores at the third month follow-ups of the patients after EWST ( < 0.001 for each). Improvements in scores were also found to be significant in NIH-CPSI, IPSS, and IIEF-EF at the 12th month evaluation. When the patients were evaluated according to the number of Li-ESWT sessions they received, the IPSS score average of the patient group who received 12 sessions of Li-ESWT was found to be lower than the patients who received 6 sessions of Li-ESWT (5.67 ± 2, 30 vs 4.51 ± 2.21; = 0.005). There was no significant difference in the IIEF-EF and IPSS scores in the 12th month evaluations of the patients, but the mean NIH-CPSI score was found to be higher in the group that received 12 sessions of Li-ESWT ( = 0.003).
Li-ESWT in the treatment of CP/CPPS patients shows positive improvements in urinary symptoms, erectile function, and quality of life in patients unresponsive to other medical treatments. The increase in the number of sessions does not seem to influence the symptoms of the patients.
本研究旨在评估李-ESWT 治疗慢性前列腺炎/慢性骨盆疼痛综合征(CP/CPPS)患者的长期疗效,并比较不同治疗方案对疗效的影响。
回顾性分析 2019 年 12 月至 2021 年 1 月期间因 CP/CPPS 症状就诊于泌尿外科门诊的 18 岁以上男性患者的资料。采用国际前列腺症状评分(IPSS)和国际勃起功能指数-勃起功能(IIEF-EF)问卷评估勃起功能。所有患者均接受 Medispect Bold Li-ESWT 治疗。比较每周一次治疗 6 次和每周两次治疗 12 次的患者治疗反应。
本研究共纳入 129 例患者。ESWT 后第 3 个月,NIH-CPSI、IPSS 和 IIEF-EF 评分均显著改善(每项均<0.001)。第 12 个月评估时,NIH-CPSI、IPSS 和 IIEF-EF 评分也有显著改善。根据患者接受的 Li-ESWT 次数进行评估时,接受 12 次 Li-ESWT 的患者的 IPSS 评分平均值低于接受 6 次 Li-ESWT 的患者(5.67±2,30 与 4.51±2.21;=0.005)。第 12 个月评估时,IIEF-EF 和 IPSS 评分无显著差异,但接受 12 次 Li-ESWT 的患者的 NIH-CPSI 评分平均值较高(=0.003)。
Li-ESWT 治疗对其他药物治疗无效的 CP/CPPS 患者的尿路症状、勃起功能和生活质量均有积极改善。增加治疗次数似乎不会影响患者的症状。